Assess whether a CMO finding is a delay or a refuse-to-file risk (d502cf)

Situation

CMC change-control owner in a safety team sitting on a new disproportionate signal has one working extract — CMC comparability package for a site change — after a CMO 483 that maps to the NDA CMC module. If CMC comparability package for a site change cannot support a CMO finding is, the honest Pharma & Life Sciences output is hold.

Decision

CMC change-control owner in a safety team sitting on a new disproportionate signal must choose A CMO finding is a delay / A refuse-to-file risk using CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• CMC change-control owner can defend A CMO finding is a delay from CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module in a Pharma & Life Sciences challenge.
• CMC change-control owner cannot defend A CMO finding is a delay from CMC comparability package for a site change; A refuse-to-file risk is what the extract actually supports after a CMO 483 that maps to the NDA CMC module.
• A CMO 483 that maps to the NDA CMC module never reached the population in CMC comparability package for a site change — reopen intake, do not close a CMO finding is.
• Two facts in CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module conflict for CMC change-control owner; hold this Clinical and Evidence Strategy file.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against a CMO 483 that maps to the NDA CMC module and write the one fact that would move a CMO finding is for CMC change-control owner.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module). The follow-on Clinical and Evidence Strategy action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.